Asia-Pacific Model UN, Sydney Agenda 1Resolution.by Prakriti Dhakal | 06-08-2018 01:39 |
|---|
|
Its so pleasure to be delegate of USA in AMUNC, we had prepared resolution paper which is really useful, please go through it. Working Paper 2.X Committee: World Health OrganisationTopic: The Implication of Amendments to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Technology on Genetic R&D. Proposer: India Signatories: Australia, China, Japan, United States of America. Preambles and Problem Identification: Recalling Article 27 of the Universal Declaration of Human Rights (UDHR) on the right to enjoy and share in scientific advancement and its benefits, Centred on the prevention of the irresponsible use of CRISPR, Recognising the possible risks and effects of future generations and unintended negative genetic ramifications, Alarmed by the possibilities of biosecurity risks/threat due to such accessibility with the information shared, Keeping in mind the ethical implications regarding germline modification and its respective effects on future generations of the human race, Aware of heredity?s powerful role in health and disease which deliver many advantages and help improve the quality of life, Fully alarmed by the importance of the availability of a consent medical framework for all participants and an explicit code of practice which must be enforced, Emphasising the proposed principle of transnational cooperation in human genome editing which includes respect for differing national policies, Recognising the urgent need for research into, and applications of, genomics in order to promote benefits that accrue to human beings; Solution/s: 1. Endorses the following principles from the National Academy of Science to underline oversight systems, research on, and the clinical uses of human genome editing to align the framework with humanitarian and societal values which include the seven governance principles on human genome editing; 2. Recommends the implementation of a Code of Practice to create guidance about licensed activities and the practitioners of CRISPR technology which includes: a. Principles for licensed centres which includes: i. Treating prospective and current patients and donors with respect and adhering to the seven governance principles; ii. Respect their personal information; iii. Respect special status of the embryo when conducting licensed activities; iv. Inform them an up-to-date information to let them decide; v. Ensure informed consent is present before carrying the licensed activity; vi. Ensure the equipment and procedures used in the conduct are safe, secure, and suitable for the CRISPR/Cas9 gene edit; vii. Conduct all licensed activities with regard for the regulatory framework treatment under each national governments commission; b. Practitioners responsible or the person in charge have the following requirements: i. Qualified by training and experience; ii. Suitable practices are used in the course of activities; iii. Authorize storage of gametes, embryos or human admixed embryos; c. Guidance to help clinics deliver safe, effective, and legally compliant treatment and research; i. Strict procedures to maintain hygiene and prevent cross-contamination in the performance of CRISPR research; ii. Extensive training for CRISPR practitioners before the carrying out of the research to minimise ; 3. Emphasises the need of the compulsory consent medical framework to be implemented in all current and future CRISPR research studies: a. All participants are entitled to full disclosure of information about the study; b. Participants have the right to reversible action; c. All participants are involved in the study on a voluntary basis only; d. Researchers in the study must hold a valid license; 4. Endorses every regulations related to CRISPR technology to be under the following standards such as but not limited to: a. The Ethical Review of Biomedical Research involving Human Subjects in 2007; b. National Institutes of Health (NIH) Human Embryo Research Panel; c. National Academies of Sciences, Engineering, and Medicine?s Guidelines for Human Embryonic Stem Cell Research; d. International Regulatory Board Review; e. Nuremburg Code, Helsinki Declaration, and CIOMS/WHO International Ethical Guidelines on Biomedical Research involving Human Subjects; 5. Emphasises the need of setting mandatory requirements for hospitals running clinical trials for CRISPR technology which may include but not limited to: a. Establish internal rules and standards of procedures for administering clinical studies; b. Require a Clinical Study Administration Committee to make supervisory decisions over study-related matters; c. Allocating funding of clinical studies must be channeled to a dedicated and monitored hospital account and not a particular clinical department or an individual physician, according to the new rules; d. All clinical study projects must be approved before the implementation; 6. Calls upon countries to conduct a rigorous oversight during clinical trials of the effects of the procedure on the participants undergoing CRISPR-Cas9 technology; a. Monitoring procedures executed at frequent intervals throughout the duration of the research study; 7. Recommends funding of human genome-editing in particular the CRISPR-Cas9 technology including funding to support near-term research and strategies for: a. Identifying research areas and classify the priorities; b. Developing communication in the implementation of the CRISPR-Cas9 technology; 8. Further recommends the funding to be aimed at the understanding of various aspects in regards to human genome editing and its uses while incorporating the efficacy of efforts to build communication and engagement on these issues into regulatory infrastructures; 9. Requests all the member states to do clinical trials on somatic cells but only research on germ cells for an arbitrary time frame and as a follow up of result to apply on clinical trials; |
